Company Overview and News

 
Eye on Stock - IFCA MSC

2018-08-11 thestar.com.my
IFCA MSC Bhd (code: 0023) has put in a positive performance over the last couple of sessions, with the week’s trading high of 32 sen achieved yesterday.
0023

 
KLCI turns negative as trade war anxiety weighs

2018-07-05 theedgemarkets
KUALA LUMPUR (July 5): The FBM KLCI turned negative at midday break today in tandem with most regional markets, on investors’ anxiety ahead of the Friday deadline for additional U.S. tariffs on Chinese products.
PBLOF MLYBY SPMXF MLYNF UPBMF BATS 4162 1163 1295 2089 9334 0023 1155 5139 SPMXY 3883 3301 0900 0026 1899 2836 3719

 
Telekom Malaysia, Axiata lift KLCI despite shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI rose at midday break today, lifted by gains at select index-linked blue chips, including Telekom Malaysia Bhd and Axiata Group Bhd, against the backdrop of weaker regional markets.
HLFBF 7084 1082 5031 BATS 4162 1163 0023 KLKBY 2445 4588 4863 5347 3867 0037 0026 TNABY 6888 5819 AXXTF MYTEF TNABF 3719

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...